Ken Belotsky

Ken Belotsky is a serial entrepreneur and venture investor with a strong track record of co-founding and leading companies to successful exits, including BrightConsult (acquired by Incadea GmbH) and Bright Box (acquired by Zurich Insurance Group). His career highlights a focus on technology, particularly in the automotive software sector, before transitioning to biotech. wonderlandconference+2

He is a prominent figure in the psychedelic biotech investment space, serving as a Founding Partner at Negev Capital, a fund dedicated to early-stage investments in novel psychedelic medications for neuropsychiatric disorders. He actively supports companies focused on the thoughtful, responsible, and therapeutic use of psychedelic compounds, helping them navigate development and secure funding. negevcap+3

As CEO and Co-founder of Negev Labs, a biotech venture studio, Ken is at the forefront of developing neuroplastogens—a new class of psychedelic-based therapeutics designed to promote neural remodeling without hallucinogenic effects. This initiative aims to address unmet clinical needs in mental health, Parkinson's, and ADHD by accelerating the development of accessible and convenient treatments. negevlabs+2

Ken demonstrates a commitment to innovation through strategic partnerships, such as Negev Labs' collaboration with the Alexander Shulgin Research Institute for access to a vast library of novel compounds, and an R&D partnership with Hadassah Brain Labs Center for Psychedelic Research. His work aims to revolutionize psychiatric care by bridging scientific discovery with accessible therapeutic solutions. negevlabs+1